Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days the report can be obtained for the test Lung Cancer Basic Panel by NGS is 14 days.

What are the prerequisites for the test Lung Cancer Basic Panel by NGS

  • Specimen Type: Formalin-fixed, paraffin-embedded (FFPE) tissue block or 10 unstained slides with at least 20% tumor content
  • Specimen Stability: Specimens must be received within 14 days of collection
  • Specimen Storage: FFPE blocks should be stored at room temperature
  • Requisition Form: Completed requisition form with patient information, clinical history, and relevant test request
  • Insurance Information: Provide insurance information for billing purposes
  • Consent Form: Signed consent form for genetic testing, if required

What are the measure values for the test Lung Cancer Basic Panel by NGS

  • EGFR (Exon 18, 19, 20, 21): Mutations Detected or Not Detected
  • KRAS (Exon 2, 3, 4): Mutations Detected or Not Detected
  • BRAF (V600): Mutations Detected or Not Detected
  • ALK Rearrangement: Positive or Negative
  • ROS1 Rearrangement: Positive or Negative

What does this test Lung Cancer Basic Panel by NGS identify?

  • EGFR gene mutations: This panel identifies mutations in the EGFR gene, which can help determine the most effective treatment options for lung cancer patients. EGFR mutations are common in non-small cell lung cancer and can be targeted with specific drugs.
  • ALK gene rearrangements: The test also looks for rearrangements in the ALK gene, which can be found in a subset of non-small cell lung cancers. Detection of ALK gene rearrangements can help guide treatment decisions, as there are targeted therapies available for this mutation.
  • ROS1 gene rearrangements: This panel includes testing for ROS1 gene rearrangements, which are present in a small percentage of non-small cell lung cancer cases. Identifying ROS1 rearrangements can help determine the most appropriate treatment options for these patients.
  • BRAF gene mutations: The test also screens for mutations in the BRAF gene, which are found in a subset of non-small cell lung cancers. Detection of BRAF mutations can impact treatment decisions, as there are targeted therapies available for this mutation.
  • PDL1 expression levels: The panel evaluates the expression levels of PD-L1, a protein that can help predict the response to immunotherapy in lung cancer patients. High levels of PD-L1 expression may indicate a better response to certain immunotherapy drugs.

Why is this test Lung Cancer Basic Panel by NGS taken?

  • This test is taken to help diagnose and guide treatment decisions for patients with lung cancer.
  • NGS (Next-Generation Sequencing) technology is used to analyze genetic mutations and alterations in the tumor cells.
  • The panel includes genes known to be involved in lung cancer development and progression.
  • Results from this test can help determine the most effective targeted therapies for the patient.
  • It can also provide information on potential resistance to certain treatments.

No FAQs available.

Customer Google Rating